of the Original Report is not being amended or changed. On July 31, 2026 , IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or othe…

Results of Operations and Financial Condition. On July 31, 2026 , IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise sub…

Results of Operations and Financial Condition. On May 1, 2026 , IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subj…

Results of Operations and Financial Condition. On February 10, 2026, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherw…

Other Events. On December 5, 2025, the Board of Directors of IRADIMED CORPORATION declared a special cash dividend on the Company's outstanding common stock of $0.50 per share. The special dividend is payable on December 30, 2025, to shareholders of record at the close of business on December 17, 2025. The information in this Item 8.01, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the lia…

Results of Operations and Financial Condition. On November 3, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherw…

director — Anthony Vuoto: Anthony Vuoto retired as a director and was succeeded by Joe Kiani.

Results of Operations and Financial Condition. On August 1, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise sub…

Results of Operations and Financial Condition. On May 5, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subje…

Results of Operations and Financial Condition. On February 13, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended December 31, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherw…

Results of Operations and Financial Condition. ​ On January 10, 2025, iRadimed Corporation issued a press release (the “Press Release”) announcing its preliminary unaudited revenues for the fourth quarter 2024 and full-year 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. ​ The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E…

Results of Operations and Financial Condition. On October 31, 2024, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherw…

Results of Operations and Financial Condition. On August 1, 2024, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise sub…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 5, 2024, IRADIMED CORPORATION, a Delaware corporation (the “ Company ”), received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) to transfer the listing of the Company’s common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective as of the open of business on June 14, 2024. The Company’s common stock will continue…

Entry into a Material Definitive Agreement. On May 29, 2024, IRADIMED CORPORATION, a Delaware corporation (the “ Company ”), entered into that certain Amendment to Susi, LLC Lease Agreement (the “ Lease Amendment ”) with SUSI, LLC, a Florida limited liability company(the “ Landlord ”), controlled by the Company’s President, Chief Executive Officer, and Chairman of the Board, Roger Susi, which amended that certain Susi, LLC Lease Agreement (the “ Lease ”), dated as of January 17, 2014, related…

Results of Operations and Financial Condition. On May 2, 2024, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subje…

Results of Operations and Financial Condition. On February 8, 2024, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the fourth quarter and full year ended December 31, 2023. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…

Other Events. On December 12, 2023, Iradimed Corporation (the “Company”) announced that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company’s outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the first installment of the quarterly dividend are payable on January 12, 2024, to shareholders of record at the close of business on December 18, 2023. A cop…

The filing describes a new compensation recovery policy, not a management change.

Results of Operations and Financial Condition. On November 3, 2023, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the first quarter ended September 30, 2023. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or…

Results of Operations and Financial Condition. On August 3, 2023, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the first quarter ended June 30, 2023. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwi…

Results of Operations and Financial Condition. On May 4, 2023, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the first quarter ended March 31, 2023. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise…

Entry into a Material Definitive Agreement. On February 2, 2023, iRadimed Corporation (the “Company”) entered into a reinstatement and amendment (the “Reinstatement”) to the previously announced sale and purchase agreement with O Property, Ltd., a Florida limited partnership (the “Purchase Agreement”) dated as of November 1, 2022, pursuant to which the parties agreed to consummate a sale of real property located in Orange County, Florida. Pursuant to the terms of the Reinstatement, the partie…

Results of Operations and Financial Condition. On February 2, 2023, iRadimed Corporation issued a press release (the “Press Release”) announcing its financial results for the fourth quarter ended December 31, 2022, and 2023 guidance. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…

Results of Operations and Financial Condition. On January 18, 2023, iRadimed Corporation issued a press release (the “Press Release”) announcing its preliminary financial results for the fourth quarter ended December 31, 2022, and 2023 guidance. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as a…